Celsion Corporation (NASDAQ:CLSN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday.
According to Zacks, “Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. “
A number of other brokerages have also weighed in on CLSN. Maxim Group raised shares of Celsion Corporation from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research note on Wednesday, October 4th. ValuEngine raised shares of Celsion Corporation from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $12.63.
Shares of Celsion Corporation (NASDAQ CLSN) opened at 3.89 on Tuesday. The company’s 50 day moving average price is $2.44 and its 200 day moving average price is $1.62. The stock’s market capitalization is $32.49 million. Celsion Corporation has a one year low of $0.19 and a one year high of $6.06.
An institutional investor recently bought a new position in Celsion Corporation stock. Sabby Management LLC purchased a new position in shares of Celsion Corporation (NASDAQ:CLSN) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 108,843 shares of the biotechnology company’s stock, valued at approximately $223,000. Sabby Management LLC owned approximately 1.30% of Celsion Corporation at the end of the most recent reporting period. 7.47% of the stock is currently owned by institutional investors.
Celsion Corporation Company Profile
Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study).
Receive News & Ratings for Celsion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.